Search

Zentalis Pharmaceuticals Inc

Slēgts

3.79 -0.26

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.74

Max

3.96

Galvenie mērījumi

By Trading Economics

Ienākumi

-42M

-78M

EPS

-0.59

Darbinieki

106

EBITDA

-42M

-77M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+131.15% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

20M

351M

Iepriekšējā atvēršanas cena

4.05

Iepriekšējā slēgšanas cena

3.79

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. aug. 23:56 UTC

Community Healthcare Trust Inc. shares are lower in after-market hours amid broader market caution related to geopolitical tensions and new U.S.-Iran sanctions.

2026. g. 24. aug. 23:56 UTC

Ares Capital Corp shares are trading roughly flat in after-hours. The stock remains above its 20-day moving average amid broader market caution.

2026. g. 24. aug. 23:56 UTC

Social Media

DICK'S Sporting Goods shares are higher in after-market trading as investors await earnings announcement tomorrow, despite earlier pulling back from a session high.

2026. g. 24. aug. 23:56 UTC

Dillard's Inc shares are lower in after-market hours amid cautious market sentiment influenced by geopolitical tensions and economic concerns.

2026. g. 24. aug. 23:56 UTC

Axon Enterprise Inc. shares advanced in after-market trading, following a higher close on Monday amid heightened market caution regarding U.S.-Iran relations and new sanctions.

2026. g. 24. aug. 23:56 UTC

Dycom Industries Inc shares are higher in after-market trading, reflecting a positive shift after five consecutive sessions of lower closes.

2026. g. 24. aug. 23:56 UTC

Vontier Corp shares traded roughly flat in after-market hours, remaining within a routine range since Monday's close.

2026. g. 24. aug. 23:56 UTC

Resmed Inc. shares are lower in after-market hours amid weak trading sentiment. No specific company news was identified to explain the decline.

2026. g. 24. aug. 23:56 UTC

Morgan Stanley shares are higher in after-market trading following Monday's close. The stock reached a session high earlier in the session.

2026. g. 24. aug. 23:56 UTC

Kanzhun Ltd shares increased in after-market trading, despite no specific news. Investor caution remains amid concerns over U.S.-Iran relations and economic implications.

2026. g. 24. aug. 23:56 UTC

Gogo Inc. shares are lower in after-market trading, continuing a decline since Monday amid broader market caution over geopolitical tensions and oil supply concerns.

2026. g. 24. aug. 23:56 UTC

Textron Inc shares are lower in after-market hours amid broader market caution linked to U.S.-Iran tensions and new sanctions affecting oil supply.

2026. g. 24. aug. 23:56 UTC

Dominion Energy shares are higher in after-market trading, reflecting a modest increase since Monday's close. The stock remains below its 20-day moving average.

2026. g. 24. aug. 23:56 UTC

Chipotle Mexican Grill Inc shares are lower in after-market hours amid broader market caution linked to geopolitical tensions and new sanctions affecting economic conditions.

2026. g. 24. aug. 23:56 UTC

Mid-America Apartment Communities shares are lower in after-market hours, reflecting notable volatility amid cautious broader market sentiment over geopolitical tensions.

2026. g. 24. aug. 23:56 UTC

Kulicke and Soffa Industries shares are higher in after-market hours, reflecting positive movement since Monday's close amid broader market caution.

2026. g. 24. aug. 23:56 UTC

Watsco Inc. shares are lower in after-market trading, continuing a trend of four consecutive daily declines and remaining below the 20-day moving average.

2026. g. 24. aug. 23:56 UTC

NRG Energy Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing investor sentiment amid concerns over U.S.-Iran relations.

2026. g. 24. aug. 23:56 UTC

Markel Group Inc. shares declined in after-market trading amid broader market caution related to geopolitical tensions and new sanctions, now 2.90% below its 20-day moving average.

2026. g. 24. aug. 23:56 UTC

Match Group Inc shares are lower in after-market trading. Broader market caution persists amid concerns over U.S.-Iran relations and oil supply disruptions.

2026. g. 24. aug. 23:56 UTC

General Mills Inc shares are lower in after-market hours, reflecting volatility amid broader market caution over U.S.-Iran relations and potential oil supply disruptions.

2026. g. 24. aug. 23:56 UTC

Correlated Moves

The US 30Y Treasury Bond Index is trading lower amid market caution over U.S.-Iran tensions and new sanctions impacting oil supply concerns.

2026. g. 24. aug. 23:52 UTC

APA Corp. shares are trading higher in after-market hours, reflecting a routine move. The stock has seen notable gains over the past month.

2026. g. 24. aug. 23:51 UTC

Hyatt Hotels Corp shares are lower in after-market hours, following a notable dip earlier amid volatility in U.S. Treasury yields and inflation concerns.

2026. g. 24. aug. 23:51 UTC

HP Inc. shares are lower in after-market hours, reversing a recent trend of higher daily closes despite an earlier rebound from session lows.

2026. g. 24. aug. 23:51 UTC

Shares of Science Applications International Corp. are lower in after-market trading, declining from earlier session peaks amid no specific news or developments.

2026. g. 24. aug. 23:51 UTC

ArcBest Corp shares are lower in after-market hours, continuing weak trading conditions. The stock remains below its 20-day moving average and near recent lows.

2026. g. 24. aug. 23:51 UTC

PENN Entertainment Inc shares are higher in after-market trading, despite remaining near the lower end of their one-month range and below the 20-day moving average.

2026. g. 24. aug. 23:51 UTC

Correlated Moves
Social Media

SPDR Gold Shares are higher in after-market hours, continuing a recent upward trend amid mixed global equity indices and rising silver prices.

2026. g. 24. aug. 23:51 UTC

Deluxe Corp's shares are lower in after-market trading, reflecting weaker performance below its 20-day moving average and near the lower end of its one-month range.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

131.15% augšup

Prognoze 12 mēnešiem

Vidējais 8.83 USD  131.15%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

5

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat